# A Safety and Efficacy Study of Brimonidine Intravitreal Implant in Geographic Atrophy Secondary to Age-related Macular Degeneration

> **NCT02087085** · PHASE2 · TERMINATED · sponsor: **Allergan** · enrollment: 310 (actual)

## Conditions studied

- Geographic Atrophy
- Macular Degeneration

## Interventions

- **DRUG:** 400 µg Brimonidine Implant
- **OTHER:** Sham

## Key facts

- **NCT ID:** NCT02087085
- **Lead sponsor:** Allergan
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-05-09
- **Primary completion:** 2018-03-30
- **Final completion:** 2018-03-30
- **Target enrollment:** 310 (ACTUAL)
- **Last updated:** 2019-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02087085

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02087085, "A Safety and Efficacy Study of Brimonidine Intravitreal Implant in Geographic Atrophy Secondary to Age-related Macular Degeneration". Retrieved via MORVS 2026-10-14 from https://api.morvs.ai/clinical/NCT02087085. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*